Helena Yu, MD, discusses the importance of zipalertinib's oral administration route for patients with EGFRm non–small cell lung cancer.

Daiichi Sankyo Company Limited (OTC:DSNKY) and AstraZeneca (NASDAQ:AZN) announced promising results from 3 clinical trials: ...

NANTES, France – June 2, 2025, 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today provided clinical updates on Tedopi®, the “off-the-shelf” neo-epitope-based therapeutic ...

Among the lung cancer population with EGFR mutations, patients with insertions at exon 20 (ex20ins) represent a significant unmet need segment. These patients often have poorer outcomes compared to ...

Cancer mRNA Vaccine Commercial Availability Expected By 2029 Says Kuick Research In New StudyDelhi, June 02, 2025 (GLOBE ...

Today, cancer stage and tumor size tell which patients will receive adjuvant chemotherapy. But the rise of biomarker testing ...

DFS at 24 months improved from 79% with observation to 96% with the use of a 14-gene assay to guide decision making about ...

Tens of thousands of patients with lung and breast cancer are to benefit from a “revolutionary” blood test on the NHS across England which can speed up access to targeted therapy. The new ‘liquid ...

The screening—known as a liquid biopsy—is being rolled out to around 15,000 patients with suspected lung cancer, NHS England ...

People with lung cancer will be offered a new blood test designed to speed up access to targeted treatments and avoid ...

A new study employing novel single-cell multimodal data revealed key insights into the tumor microenvironment predictive of NSCLC treatment response.

The new "liquid biopsy" test searches for tiny fragments of DNA that are shed by tumours into the bloodstream - it can ...